Talphera, Inc. (NASDAQ:TLPH) Short Interest Down 15.4% in February

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 75,400 shares, a decrease of 15.4% from the January 31st total of 89,100 shares. Based on an average trading volume of 94,800 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.5% of the shares of the stock are sold short.

Institutional Investors Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Rosalind Advisors Inc. bought a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera accounts for about 0.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 25th largest position. Rosalind Advisors Inc. owned about 4.47% of Talphera as of its most recent filing with the Securities & Exchange Commission. 37.67% of the stock is currently owned by institutional investors and hedge funds.

Talphera Stock Down 0.9 %

Shares of Talphera stock opened at $0.54 on Wednesday. The firm has a market capitalization of $9.11 million, a P/E ratio of -0.78 and a beta of 0.29. Talphera has a 52 week low of $0.50 and a 52 week high of $1.32. The company has a 50 day moving average price of $0.61 and a 200 day moving average price of $0.76.

Wall Street Analyst Weigh In

TLPH has been the subject of a number of recent research reports. RODMAN&RENSHAW raised shares of Talphera to a “strong-buy” rating in a report on Tuesday, January 28th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Talphera in a research report on Tuesday, January 21st. Rodman & Renshaw started coverage on Talphera in a research report on Tuesday, January 28th. They issued a “buy” rating and a $4.00 price target for the company. Finally, Maxim Group raised shares of Talphera to a “strong-buy” rating in a research report on Friday, November 8th.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.